News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Clinical

Latest News

July 25th 2018

Treating Multiple Myeloma at First Relapse

Optimizing Frontline Therapy in Multiple Myeloma

Daratumumab's Potential as Frontline Therapy for MM

Frontline Treatment Options for Multiple Myeloma

Considerations for Newly Diagnosed Multiple Myeloma

Latest Videos

Future Directions of Sickle Cell Disease Management

Future Directions of Sickle Cell Disease Management

Coverage of Older and Newer Therapies in Sickle Cell Disease

Coverage of Older and Newer Therapies in Sickle Cell Disease

Sickle Cell Disease: Cost and Access to Therapy in an Evolving Paradigm

Sickle Cell Disease: Cost and Access to Therapy in an Evolving Paradigm

Novel Biologic Therapies for Sickle Cell Disease Management

Novel Biologic Therapies for Sickle Cell Disease Management

Voxelotor's Potential as Treatment for Sickle Cell Disease

Voxelotor's Potential as Treatment for Sickle Cell Disease

Sickle Cell Disease: Challenges From the Payer Perspective

Sickle Cell Disease: Challenges From the Payer Perspective

Sickle Cell Disease: Addressing Complications and Quality of Life

Sickle Cell Disease: Addressing Complications and Quality of Life

Integrating Nonpharmacologic Treatment Options for Sickle Cell Disease

Integrating Nonpharmacologic Treatment Options for Sickle Cell Disease

Sickle Cell Disease: Hydroxyurea or L-Glutamine Oral Powder

Sickle Cell Disease: Hydroxyurea or L-Glutamine Oral Powder

Hydroxyurea's Role in Managing Sickle Cell Disease

Hydroxyurea's Role in Managing Sickle Cell Disease

CME Content

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

More News

Increasingly Improved Outcomes for Multiple Myeloma

July 25th 2018

Treating Multiple Myeloma Through Multiple Relapses

July 25th 2018

Incremental Changes in Therapy at MM Relapse

July 25th 2018

Multiple Myeloma: Approaching Treatment at First Relapse

July 25th 2018

Optimizing Treatment for MM: Transplant and Maintenance

July 25th 2018

Newly Diagnosed Multiple Myeloma: Frontline Options

July 25th 2018

Selecting Therapy for Newly Diagnosed Myeloma

July 25th 2018

Combination Therapy: Improving Multiple Myeloma Outcomes

July 25th 2018

Shared Decision-Making Tool Can Identify Best Treatment Plan for Patients With Severe Asthma

ByLaura Joszt, MA

July 21st 2018

New tools from the American College of Chest Physicians' CHEST Foundation, the Allergy & Asthma Network, and the American College of Allergy, Asthma & Immunology can help clinicians and patients to work together to choose the best treatment and increase adherence.

Sequencing Therapy in NSCLC

July 18th 2018

Using Antiangiogenic Therapy in NSCLC in the Future

July 18th 2018

Antiangiogenic Therapy in NSCLC: Addressing the Unknown

July 18th 2018

Necitumumab in Squamous NSCLC

July 18th 2018

Rationale for Ramucirumab in NSCLC

July 18th 2018

Pembrolizumab in First-Line Nonsquamous NSCLC

July 18th 2018

Antiangiogenic Therapy in NSCLC

July 18th 2018

Breakthroughs in Treating NSCLC

July 18th 2018

Key Points From the REVEL Trial in NSCLC

July 18th 2018

Considerations for Antiangiogenic Therapy in NSCLC

July 18th 2018

Evidence for Immunotherapy in Frontline NSCLC

July 18th 2018

Future Use of Antiangiogenic Agents in NSCLC

July 18th 2018

Immunotherapy and <i>VEGF</i>-Targeted Therapy in NSCLC

July 18th 2018

VEGF Inhibition in NSCLC

July 18th 2018

The Phase 3 REVEL Trial in NSCLC

July 18th 2018

Ramucirumab in Relapsed/Refractory NSCLC

July 18th 2018

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

5 Things to Know About the Oral GLP-1 Era

Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.

Alt Text

Alt Text